Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

Research output: Contribution to journalArticle

Standard

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. / Juliusson, Gunnar; Antunovic, Petar; Derolf, Asa; Lehmann, Soren; Mollgard, Lars; Stockelberg, Dick; Tidefelt, Ulf; Wahlin, Anders; Hoglund, Martin.

In: Blood, Vol. 113, No. 18, 2009, p. 4179-4187.

Research output: Contribution to journalArticle

Harvard

Juliusson, G, Antunovic, P, Derolf, A, Lehmann, S, Mollgard, L, Stockelberg, D, Tidefelt, U, Wahlin, A & Hoglund, M 2009, 'Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry', Blood, vol. 113, no. 18, pp. 4179-4187. https://doi.org/10.1182/blood-2008-07-172007

APA

CBE

Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, Tidefelt U, Wahlin A, Hoglund M. 2009. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 113(18):4179-4187. https://doi.org/10.1182/blood-2008-07-172007

MLA

Vancouver

Author

Juliusson, Gunnar ; Antunovic, Petar ; Derolf, Asa ; Lehmann, Soren ; Mollgard, Lars ; Stockelberg, Dick ; Tidefelt, Ulf ; Wahlin, Anders ; Hoglund, Martin. / Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. In: Blood. 2009 ; Vol. 113, No. 18. pp. 4179-4187.

RIS

TY - JOUR

T1 - Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

AU - Juliusson, Gunnar

AU - Antunovic, Petar

AU - Derolf, Asa

AU - Lehmann, Soren

AU - Mollgard, Lars

AU - Stockelberg, Dick

AU - Tidefelt, Ulf

AU - Wahlin, Anders

AU - Hoglund, Martin

PY - 2009

Y1 - 2009

N2 - Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit for intensive treatment because of the risk of fatal toxicity. The Swedish Acute Leukemia Registry covers 98% of all patients with AML (non-acute promyelocytic leukemia) diagnosed in 1997 to 2005 (n = 2767), with a median follow-up of 5 years, and reports eligibility for intensive therapy, performance status (PS), complete remission rates, and survival. Outcomes were strongly age and PS dependent. Early death rates were always lower with intensive therapy than with palliation only. Long-term survivors were found among elderly given intensive treatment despite poor initial PS. Total survival of elderly AML patients was better in the geographic regions where most of them were given standard intensive therapy. This analysis provides unique real world data from a large, complete, and unselected AML population, both treated and untreated, and gives background to treatment decisions for the elderly. Standard intensive treatment improves early death rates and long-term survival compared with palliation. Most AML patients up to 80 years of age should be considered fit for intensive therapy, and new therapies must be compared with standard induction. (Blood. 2009; 113: 4179-4187)

AB - Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit for intensive treatment because of the risk of fatal toxicity. The Swedish Acute Leukemia Registry covers 98% of all patients with AML (non-acute promyelocytic leukemia) diagnosed in 1997 to 2005 (n = 2767), with a median follow-up of 5 years, and reports eligibility for intensive therapy, performance status (PS), complete remission rates, and survival. Outcomes were strongly age and PS dependent. Early death rates were always lower with intensive therapy than with palliation only. Long-term survivors were found among elderly given intensive treatment despite poor initial PS. Total survival of elderly AML patients was better in the geographic regions where most of them were given standard intensive therapy. This analysis provides unique real world data from a large, complete, and unselected AML population, both treated and untreated, and gives background to treatment decisions for the elderly. Standard intensive treatment improves early death rates and long-term survival compared with palliation. Most AML patients up to 80 years of age should be considered fit for intensive therapy, and new therapies must be compared with standard induction. (Blood. 2009; 113: 4179-4187)

U2 - 10.1182/blood-2008-07-172007

DO - 10.1182/blood-2008-07-172007

M3 - Article

VL - 113

SP - 4179

EP - 4187

JO - Blood

JF - Blood

SN - 1528-0020

IS - 18

ER -